{"analyses":[{"ciLowerLimit":"0.290","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.681","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0001","pValueComment":"The priori threshold for statistical significance was 0.03426.","paramType":"Hazard Ratio (HR)","paramValue":"0.444","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% CI were not estimable due to an insufficient number of participants with events.","groupId":"OG000","lowerLimit":"39.72","upperLimit":"NA","value":"NA"},{"comment":"Median, lower and upper limit of 95% CI were not estimable due to an insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"191"}],"units":"Participants"}],"description":"Time to symptomatic progression was defined as time from the date of randomization to the date of any of the following (whichever occurred first): (a) the use of external beam radiation therapy for skeletal or pelvic symptoms, (b) the need for tumor-related orthopedic surgical intervention, (c) other cancer-related procedures (example: nephrostomy insertion, bladder catheter insertion, external beam radiation therapy, or surgery for tumor symptoms), (d) cancer-related morbid events (that is, fracture \\[symptomatic and/or pathologic\\], cord compression, urinary obstructive events), (e) initiation of a new systemic anti-cancer therapy because of cancer symptoms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with deleterious germline or gene-mutated mCSPC and BRCA alterations were randomized to receive placebo matching to niraparib and AA fixed dose combination (FDC) tablets along with AA tablets (4\\*250 mg tablet) and prednisone 5 mg tablet orally, once daily from Day 1 of Cycle 1 up to 49 cycles. Each treatment cycle consisted of 28 days.","id":"OG000","title":"BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone"},{"description":"Participants with deleterious germline or somatic HRR gene-mutated mCSPC and BRCA alterations were randomized to receive niraparib and AA FDC tablets (2\\* \\[100 mg niraparib/500 mg AA tablet\\]) along with placebo matching to AA tablet and prednisone 5 mg tablet orally, once daily from Day 1 of Cycle 1 up to 49 cycles. Each treatment cycle consisted of 28 days.","id":"OG001","title":"BRCA Subgroup: Niraparib With Abiraterone Acetate Plus Prednisone"}],"paramType":"MEDIAN","populationDescription":"BRCA FAS included all randomized participants with BRCA gene alteration classified according to their assigned treatment arm, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"From date of randomization (Day -3 to Day 1) up to approximately 49 months","title":"BRCA Subgroup: Time to Symptomatic Progression","type":"SECONDARY","unitOfMeasure":"months"}